FDA grants rolling review for Palvella's rapamycin NDA for rare condition
Go back to FDA grants rolling review for Palvella's rapamycin NDA for rare condition| (NASDAQ: PVLA) | Delayed: 138.01 -5.2 (3.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.21 | 52 Week High | $ | |||
| Open | $144.45 | 52 Week Low | $ | |||
| Day High | $144.45 | P/E | N/A | |||
| Day Low | $136.68 | EPS | $ | |||
| Volume | 184,283 | |||||
